{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-013255","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.070483+00:00","generated_at":"2026-06-04T01:48:29.382304+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Matinas BioPharma raises $10M in registered direct offering of common stock and warrants","bullets":["Sold 33,333,334 shares and warrants at $0.30/unit; gross proceeds ~$10M.","Warrants exercisable at $0.35/share for 5.5 years from issuance, starting 6 months post-closing.","Proceeds to be used for working capital and general corporate purposes.","Offering expected to close April 5, 2024; A.G.P./Alliance Global Partners sole placement agent.","Directors and officers subject to 90-day lock-up on securities transfers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-013255","json":"https://secwatch.observer/filing/0001493152-24-013255.json","markdown":"https://secwatch.observer/filing/0001493152-24-013255.md","text":"https://secwatch.observer/filing/0001493152-24-013255.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/0001493152-24-013255-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:48:29.382304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32998e927465bdfa340b140757fbfa115912b7f5","claim":"Matinas BioPharma Holdings, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Placement agent to use reasonable best efforts to sell securities; cash fee of 7.0% of aggregate pur (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024, the Company also entered into a placement agent agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/0001493152-24-013255-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"Placement agent to use reasonable best efforts to sell securities; cash fee of 7.0% of aggregate pur"},{"label":"Effective","value":"2024-04-02"}],"fact_type":"material_agreement"},{"claim_id":"5afc7365f156afba2f3c82be89f102767e497a64","claim":"Matinas BioPharma Holdings, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at 33,333,334 shares of common stock and warrants to purchase 33,333,334 shares of common stock at offe (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024, Matinas BioPharma Holdings, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (collectively, the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1582554/000149315224013255/0001493152-24-013255-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"33,333,334 shares of common stock and warrants to purchase 33,333,334 shares of common stock at offe"},{"label":"Effective","value":"2024-04-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}